MTX and Steroid as First-line Therapy for aGVHD

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital

Criteria

Inclusion Criteria:

1. Patients who are fully informed and sign informed consent by themselves or their guardians;

2. Patients receiving allogeneic hematopoietic stem cell transplantation;

3. Patients with acute graft-versus-host disease of grade II-IV were diagnosed after transplantation;

4. Patients with stable implantation of granulocytes and platelets.

5. ECOG score ≤3

Exclusion Criteria:

1. Patients with severe brain, heart, kidney or liver dysfunction unrelated to graft-versus host disease;

2. Patients with uncontrollable active infection;

3. Patients with recurrence of primary malignant hematopathy;

4. Expected survival is less than 3 months

5. Patients who have histories of severe allergic reactions

6. Pregnant or lactating women

7. The researcher judges that there are other factors that are not suitable for participating